Alnylam Pharmaceuticals
ALNY
#585
Rank
S$45.20 B
Marketcap
$352.10
Share price
1.90%
Change (1 day)
39.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.49

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.35. In 2022 the company made an earnings per share (EPS) of -$12.10 a decrease over its 2021 EPS that were of -$9.38.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.49-54.63%
2022-$12.1029.03%
2021-$9.38-3.36%
2020-$9.70-8.48%
2019-$10.607.67%
2018-$9.8539.74%
2017-$7.0512.94%
2016-$6.2438.84%
2015-$4.49-32.88%
2014-$6.70259.44%
2013-$1.86-31.25%
2012-$2.7152.94%
2011-$1.7730.77%
2010-$1.35-8.77%
2009-$1.4878.13%
2008-$0.83-70.78%
2007-$2.8599.09%
2006-$1.43-43.88%
2005-$2.55-82.33%
2004-$14.45-59.23%
2003-$35.44

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.21-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$48.66-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.20 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.35-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.20-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$4.87-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.14-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.61-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel